e-learning
resources
Glasgow 2004
Monday 06.09.2004
Cardiovascular and metabolic consequences of OSA
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The role of inflammatory mediator in exhaled breath condensate of obstructive sleep apnea
Y. Sueyasu, T. Kitajima, A. Shimada, Y. Oshita, T. Koga, T. Rikimaru, H. Aizawa (Kurume, Japan)
Source:
Annual Congress 2004 - Cardiovascular and metabolic consequences of OSA
Session:
Cardiovascular and metabolic consequences of OSA
Session type:
Thematic Poster Session
Number:
2096
Disease area:
Sleep and breathing disorders
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. Sueyasu, T. Kitajima, A. Shimada, Y. Oshita, T. Koga, T. Rikimaru, H. Aizawa (Kurume, Japan). The role of inflammatory mediator in exhaled breath condensate of obstructive sleep apnea. Eur Respir J 2004; 24: Suppl. 48, 2096
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Clinical case discussion: ERS guidelines on high flow nasal cannula in acute respiratory failure: from the clinical cases to the scientific evidence
Adherence predictors to positive airway pressure (PAP) treatment in patients with obstructive sleep apnea (OSA)
The search for realistic evidence on the outcomes of obstructive sleep apnoea
Related content which might interest you:
Reproducibility of exhaled breath condensate pH in chronic obstructive pulmonary disease
Source: Eur Respir J 2005; 25: 269-274
Year: 2005
Factors influencing airway inflammation measured by exhaled NO levels in a population with obstructive sleep apnea syndrome (OSA)
Source: Annual Congress 2010 - Biomarkers for oxidative stress, inflammation and cardiovascular function in sleep apnoea
Year: 2010
impact of continous positive airway pressure therapy on exhaled nitic oxide in obstructive sleep apnea syndrome
Source: International Congress 2019 – Clinical problems from non-malignant pleural disease to hypoventilation
Year: 2019
Effect of nasal CPAP on exhaled nitric oxide in patients with obstructive sleep apnea
Source: Eur Respir J 2007; 30: Suppl. 51, 332s
Year: 2007
Exhaled breath condensate biomarkers in COPD
Source: Eur Respir J 2008; 32: 472-486
Year: 2008
Myeloperoxidase in exhaled breath condensate reflects the status of lung parenchyma during the exacerbation of chronic obstructive pulmonary disease
Source: Eur Respir J 2005; 26: Suppl. 49, 54s
Year: 2005
Exhaled breath markers in patients with obstructive sleep apnea (OSA): baseline assessment and the impact of treatment with nasal continuous positive airway pressure
Source: Eur Respir J 2005; 26: Suppl. 49, 355s
Year: 2005
Alveolar but not airway fractional exhaled nitric oxide concentration (FENO) is decreased in obstructive sleep apnea syndrome (OSAS)
Source: Eur Respir J 2003; 22: Suppl. 45, 467s
Year: 2003
Overnight changes in exhaled carbon monoxide levels in obstructive sleep apnoea
Source: International Congress 2018 – Biomarkers for evaluating COPD
Year: 2018
Metabolomic analysis of exhaled breath condensate in diagnostics of obstructive airway diseases
Source: Annual Congress 2011 - Role of the biomarkers in airway diseases
Year: 2011
Concentration of exhaled nitric oxide (FE
NO
) in patients with obstructive sleep apnea
Source: Eur Respir J 2004; 24: Suppl. 48, 118s
Year: 2004
Cystenil-leukotrienes as markers of airway inflammation in exhaled breath condensate of asthmatic children
Source: Eur Respir J 2002; 20: Suppl. 38, 412s
Year: 2002
Oxydative stress in obstructive sleep apnea (OSA). Exhaled breath condensate (EBC) measurements (H
2
O
2
) in the follow-up of patients under CPAP. First results
Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea
Year: 2007
Exhaled breath condensate for evaluation of inflammation in COPD patients
Source: Eur Respir J 2006; 28: Suppl. 50, 35s
Year: 2006
Prediction of CF exacerbations by FeNO and non-invasive inflammatory markers in exhaled breath condensate
Source: Annual Congress 2008 - Cystic fibrosis: novel aspects of airway function and inflammation
Year: 2008
Prediction of asthma exacerbations in children by FeNO and non-invasive inflammatory markers in exhaled breath condensate
Source: Annual Congress 2008 - Assessment of inflammation, hyperresponsiveness and response to exercise in asthmatic children
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept